-- Mary Elizabeth Dallas
THURSDAY, May 23 (HealthDay News) -- Although a study in 2012
suggested a cancer drug could reverse the thinking and memory
problems associated with Alzheimer's disease, three groups of
researchers now say they have been unable to duplicate those
The teams said their research could have serious implications
for patient safety since the drug involved in the study, bexarotene
(Targretin), has serious side effects, such as major blood-lipid
abnormalities, pancreatitis, headaches, fatigue, weight gain,
depression, nausea, vomiting, constipation and rash.
"Anecdotally, we have all heard that physicians are treating their Alzheimer's patients with bexarotene, a cancer drug with severe side effects," said study co-author Robert Vassar, a professor of cell and molecular biology at Northwestern University Feinberg School of Medicine, in Chicago. "This practice should be ended immediately, given the failure of three independent research groups to replicate the plaque-lowering effects of bexarotene."
The U.S. Food and Drug Administration approved bexarotene in
1999 to treat refractory cutaneous T-cell lymphoma. Once approved,
however, the drug also was available by prescription for
The 2012 study suggested that bexarotene was able to rapidly
reverse the build-up of beta amyloid plaques in the brains of mice.
The authors of the initial study concluded that treatment with the
drug might reverse the cognitive and memory problems associated
with the development of Alzheimer's.
Sangram Sisodia, a professor of neurosciences at the University
of Chicago and a study co-author of the latest research, admitted
being skeptical about the initial findings.
"We were surprised and excited -- even stunned -- when we first saw these results presented at a small conference," Sisodia said in a University of Chicago Medical Center news release. "The mechanism of action made some sense, but the assertion that they could reduce the areas of plaque by 50 percent within three days and by 75 percent in two weeks seemed too good to be true."
In attempting to duplicate the findings, the research teams
found that they were indeed too good to be true.
"We all went back to our labs and tried to confirm these promising findings," Sisodia said. "We repeated the initial experiments -- a standard process in science. Combined results are really important in this field. None of us found anything like what they described in the 2012 paper."
Researchers at the University of Chicago, Northwestern
University, Massachusetts General Hospital, Washington University
in St Louis and the University of Tubingen in Germany reported in
the May 24 issue of the journal
Sciencethat they did not find any reduction in beta amyloid
plaques during or after treatment with bexarotene in three
different strains of mice.
Bexarotene has never been tested on people as a treatment for
Alzheimer's disease. Currently, there is no cure or effective
treatment for the progressive condition, which affects an estimated
5.3 million Americans.
The U.S. National Institutes of Health provides more information
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.